title: Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient.
authors.forename: P M
authors.initials: PM
authors.lastname: Rubio
authors.forename: C
authors.initials: C
authors.lastname: Labrandero
authors.forename: S
authors.initials: S
authors.lastname: Riesco
authors.forename: D
authors.initials: D
authors.lastname: Plaza
authors.forename: B
authors.initials: B
authors.lastname: González
authors.forename: G M
authors.initials: GM
authors.lastname: Muñoz
authors.forename: A
authors.initials: A
authors.lastname: Sastre
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D008297:Male; D010490:Pericardial Effusion / Q000209:etiology / Q000517:prevention & control*; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012720:Severity of Illness Index; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab